Absence of Severe Complications From SARS-CoV-2 Infection in Children With Rheumatic Diseases Treated With Biologic Drugs
J Rheumatol
.
2021 Aug;48(8):1343-1344.
doi: 10.3899/jrheum.200483.
Epub 2020 Apr 25.
Authors
Giovanni Filocamo
1
,
Francesca Minoia
2
,
Simone Carbogno
2
,
Stefania Costi
3
,
Micol Romano
3
,
Rolando Cimaz
;
Pediatric Rheumatology Group of the Milan Area
Affiliations
1
Fondazione IRCCS Cà Granda ospedale Maggiore Policlinico; giovanni.filocamo@policlinico.mi.it.
2
Fondazione IRCCS Cà Granda ospedale Maggiore Policlinico.
3
ASST G.Pini-CTO.
PMID:
32335512
DOI:
10.3899/jrheum.200483
No abstract available
Publication types
Letter
Comment
MeSH terms
Antirheumatic Agents* / adverse effects
Biological Products* / therapeutic use
COVID-19*
Child
Humans
Rheumatic Diseases* / drug therapy
SARS-CoV-2
Substances
Antirheumatic Agents
Biological Products